AVDL - Avadel Pharmaceuticals plc (AVDL) Q1 2024 Earnings Call Transcript
2024-05-08 12:52:04 ET
Avadel Pharmaceuticals plc (AVDL)
Q1 2024 Earnings Conference Call
May 08, 2024 08:30 am ET
Company Participants
Austin Murtagh - Director at Stern Investor Relations
Gregory Divis - CEO
Richard Kim - Chief Commercial Officer
Thomas McHugh - CFO
Conference Call Participants
Andrew Tsai - Jefferies
François Brisebois - Oppenheimer
Ami Fadia - Needham & Company
David Amsellem - Piper Sanger
Marc Goodman - Leerink Partners
Ashwani Verma - UBS
Oren Livnat - H.C. Wainwright
Chase Knickerbocker - Craig Hallum
Myriam Belghiti - LifeSci Capital
Matthew Kaplan - Ladenburg Thalmann & Co. Inc.
Presentation
Operator
Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. Thank you. You may begin.
Austin Murtagh
Good morning, and thank you for joining us on our conference call to discuss Avadel's first quarter 2024 earnings. As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties are described in Avadel's public filings under the Exchange Act included in the Form 10-K for the year ended December 31, 2023, which was filed on February 29, 2024, and subsequent SEC filings.
Except as required by law, Avadel undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise. On the call today are Greg Divis, Chief Executive Officer; Richard Kim, Chief Commercial Officer; and Tom McHugh, Chief Financial Officer. At this time, I'll turn the call over to Greg.
Gregory Divis
Thank you, Austin. Good morning, everyone, and thank you for joining us to review our first quarter 2024 results. Following my opening remarks, Richard will provide an update on our launch progress, including our key metrics through March 31. Tom will then review our Q1 financial results, and we will conclude with a question-and-answer session....
Avadel Pharmaceuticals plc (AVDL) Q1 2024 Earnings Call Transcript